Comparison of Oliceridine and Morphine in Postoperative Analgesia in Laparoscopic Total Hysterectomy, a Randomized Double-Blind Controlled Trial

腹腔镜全子宫切除术后镇痛中奥利西啶与吗啡的比较:一项随机双盲对照试验

阅读:1

Abstract

PURPOSE: Compare the analgesic efficacy and safety profiles of oliceridine and morphine in patient-controlled intravenous analgesia (PCIA) after laparoscopic total hysterectomy. MATERIALS AND METHODS: This prospective, double-blind trial randomly allocated 60 patients undergoing elective laparoscopic total hysterectomy in a 1:1 ratio to receive either oliceridine (group O) or morphine (group M) via PCIA. The primary endpoint was cough numerical rating scale (NRS) scores 6 h postoperatively. Secondary outcomes included cough/resting NRS scores at 0.5, 2, 6, 12, 24, and 48 h (6 h cough NRS score excluded); 24-hour postoperative recovery quality using 15-item Quality of Recovery (QoR-15) scale. Exploratory indicators including hemodynamic parameters and peripheral capillary oxygen saturation (SpO(2)) post intravenous analgesic loading dose. Safety indicators represented by the incidence of adverse events occurring within 72 hours postoperatively. RESULTS: Group O demonstrated superior early analgesia with lower resting NRS (1.0 [1.0,1.0] vs 1.5 [1.0,2.0]; P = 0.019) and cough NRS (1.0 [1.0-2.0] vs 2.5 [1.0-3.0]; P = 0.003) at 0.5 h compared with group M, and analgesic efficacy was comparable thereafter (all P > 0.05). Group O exhibited lower nausea/vomiting (33.3% vs 73.3%, P = 0.002) and constipation (20.0% vs 53.3%, P = 0.007) rates, along with higher 24-h QoR-15 scores (125.27 ± 10.11 vs 119.67 ± 8.49; P = 0.024). Higher SpO(2) in group O at 5 min (P = 0.003) and 10 min (P = 0.033) postloading doses. Meanwhile, group M demonstrated transient heart rate (HR) elevation at 5 min postloading dose, whereas group O exhibited no significant HR increases at any time point. CONCLUSION: Oliceridine demonstrates analgesic efficacy comparable to morphine after laparoscopic total hysterectomy but exhibits superior safety by significantly reducing opioid-related adverse events and potentially accelerating postoperative recovery.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。